delay
immun
reconstitut
viral
infect
remain
signific
caus
morbid
mortal
follow
allogen
natur
histori
immun
reconstitut
alter
allogen
transplant
gvhd
well
immunosuppress
therapi
although
viral
infect
also
common
risk
sever
diseas
higher
mud
due
sever
depress
immun
respons
addit
agent
atg
condit
regimen
mud
transplant
associ
reduc
incid
gvhd
increas
risk
delay
immun
also
tcr
deplet
prophylaxi
gvhd
achiev
signific
success
haploident
hsct
associ
increas
risk
viral
aim
studi
compar
incid
viru
infect
outcom
children
underw
hsct
mrd
haploident
donor
retrospect
analyz
viral
infect
outcom
one
hundr
pediatr
patient
median
year
underw
allogen
hsct
januari
septemb
patient
divid
four
subgroup
patient
transplant
mrd
n
hla
n
hla
n
haploident
donor
n
patient
characterist
summar
tabl
addit
donor
type
whole
group
divid
phase
infect
year
identifi
separ
viral
infect
episod
differ
virus
defin
multipl
viral
infect
recurr
pathogen
count
multipl
infect
myeloabl
condit
regimen
consist
busulfan
mgkg
plu
cyclophosphamid
mgkg
ric
regimen
consist
fludarabin
mgkg
plu
busulfan
mgkg
cyclophosphamid
mgkg
serotherapi
consist
atg
mgkg
consist
ric
regimen
atg
day
fludarabin
day
thiotepa
day
melphalan
day
deplet
prevent
ptld
gvhd
rtx
ad
condit
regimen
msc
infus
suppress
alloreact
donor
respons
use
abil
promot
angiogenesi
support
facilit
engraft
serolog
herpesvirus
hsv
ebv
cmv
adv
parvoviru
hiv
hepat
viru
hav
hbv
hcv
assess
patient
transplant
pcr
screen
test
cmv
ebv
parvoviru
adv
perform
routin
weekli
transplant
period
inpati
outpati
symptomat
bk
viru
test
urin
blood
routin
patient
mud
mrd
transplant
patient
test
clinic
suspicion
hemorrhag
cystiti
adv
antigen
cmv
pcr
test
stool
patient
diarrhea
pcr
test
cmv
carri
routin
everi
day
period
adv
parvoviru
dna
pcr
perform
smart
cyclercepheid
pcr
ebv
bk
viru
dna
pcr
perform
versant
kpcr
molecular
systemsiemen
pcr
pcr
perform
qqiagen
pcr
cmv
reactiv
defin
posit
plasma
cmv
dna
detect
pcr
versant
kpcr
molecular
systemsiemen
use
taqman
primer
cutoff
level
treatment
dna
copiesml
cmv
diseas
defin
clinic
symptom
associ
detect
cmv
fluid
lavag
fluid
biopsi
specimen
obtain
affect
organ
except
cmv
retin
diagnos
retin
examin
experienc
patient
receiv
acyclovir
prophylaxi
cmv
infect
discontinu
immunosuppress
ivig
given
weekli
inpati
treatment
thereaft
accord
immunoglobulin
g
igg
level
gl
lymphocyt
count
lymphocyt
count
day
analyz
patient
analysi
immun
reconstitut
quantifi
b
nk
cell
perform
day
patient
neutrophil
engraft
day
defin
first
day
three
consecut
day
absolut
neutrophil
count
platelet
engraft
day
defin
first
three
consecut
day
without
transfus
support
least
day
lymphocyt
engraft
defin
first
day
three
consecut
day
absolut
lymphocyt
count
acut
chronic
gvhd
defin
grade
accord
ebmt
gvhd
prophylaxi
consist
mostli
csa
alon
csa
mtx
combin
mrd
mud
transplant
wherea
mmf
use
haploident
donor
transplant
mmf
ad
routin
patient
abo
mismatch
donor
gvhd
prophylaxi
day
data
analyz
use
spss
version
window
spss
chicago
il
usa
statist
packag
categor
data
present
frequenc
percentag
continu
variabl
present
median
minimum
maximum
comparison
among
group
made
continu
variabl
distribut
test
categor
variabl
test
use
comparison
depend
variabl
p
valu
consid
statist
signific
method
use
surviv
analysi
one
hundr
pediatr
patient
undergo
hsct
enrol
studi
median
durat
month
rang
month
main
diagnosi
hla
dispar
donor
type
condit
regimen
use
corticosteroid
atg
median
cell
graft
engraft
day
neutrophil
platelet
lymphocyt
lymphocyt
count
day
day
lymphocyt
count
exist
acut
chronic
gvhd
accord
donor
type
summar
tabl
median
engraft
day
thrombocyt
lymphocyt
achiev
day
earlier
patient
receiv
patient
receiv
mrd
mud
hsct
differ
statist
differ
tabl
lymphocyt
count
day
day
lymphocyt
count
greater
significantli
differ
four
group
tabl
immunophenotyp
analysi
reveal
progress
slow
increas
lymphocyt
subset
count
day
later
time
point
patient
data
day
show
delay
immun
reconstitut
cell
helper
cell
cytotox
cell
b
cell
nk
cell
recoveri
found
fast
reach
normal
valu
within
day
median
rang
cell
began
recov
day
median
rang
cell
rang
cytotox
cell
helper
cell
reach
normal
valu
day
median
rang
b
cell
found
still
low
month
transplant
lymphocyt
subset
shown
tabl
cumul
incid
acut
grade
grade
gvhd
whole
group
forti
percent
patient
sever
acut
gvhd
iii
children
sever
acut
gvhd
develop
least
one
viral
infect
develop
multipl
viral
infect
chronic
gvhd
observ
seven
patient
six
one
viral
infect
two
multipl
viral
infect
sever
chronic
gvhd
observ
six
patient
tabl
among
patient
five
least
one
viral
infect
four
multipl
infect
one
hundr
viral
episod
document
within
median
month
rang
month
patient
evid
viral
infect
one
viral
reactivationinfect
two
three
two
four
viral
reactivationsinfect
differ
virus
viral
reactivationsclin
infect
occur
first
month
tabl
recipi
graft
recipi
haploident
donor
graft
seem
higher
incid
multipl
viral
infect
mrd
graft
vs
p
found
increas
risk
multipl
viral
infect
among
patient
total
lymphocyt
count
day
vs
p
cmv
preval
infect
n
follow
bk
viru
n
among
transplant
group
cmv
detect
patient
patient
diagnos
cmv
reactiv
cmv
appear
often
among
recipi
mrd
graft
p
patient
patient
hsct
patient
hsct
posit
cmv
reactivationinfect
wherea
patient
posit
cmv
reactivationinfect
tabl
fifteen
case
associ
symptom
grade
acut
gvhd
case
associ
symptom
grade
acut
gvhd
time
viru
detect
among
patient
cmv
diseas
four
patient
one
associ
cmv
hepat
develop
cmv
pneumonia
fatal
outcom
two
patient
cmv
retin
three
patient
cmv
enter
treat
intraven
ganciclovir
success
bk
viru
second
seen
infect
bk
hemorrhag
cystiti
diagnos
hsct
patient
patient
posit
bk
viru
day
twenti
patient
posit
day
two
patient
posit
day
bk
viru
detect
often
among
recipi
mrd
graft
p
patient
patient
hsct
patient
hsct
posit
bk
viru
tabl
major
patient
detect
bk
viru
urin
mild
clinic
symptom
three
patient
diagnos
bk
viru
nephropathi
treat
cidofovir
one
viral
clearanc
cidofovir
treatment
second
one
viral
clearanc
leflunomid
quinolon
treatment
third
one
still
leflunomid
quinolon
treatment
ebv
detect
pcr
blood
nine
patient
none
develop
lymphoprolif
disord
rest
associ
asymptomat
viremia
tabl
ebv
infect
found
statist
differ
mrd
hsct
p
treatment
children
show
ebv
replic
consist
reduct
immunosuppress
rituximab
treatment
three
children
vzv
infect
seen
group
acyclovir
prophylaxi
infect
detect
one
patient
patient
develop
pneumonia
rash
fever
lymphadenopathi
parot
sign
enceph
treat
ganciclovir
ivig
success
altogeth
patient
found
posit
parvoviru
pcr
period
seven
patient
day
four
patient
day
one
patient
day
patient
receiv
ivig
treatment
clear
viremia
month
two
patient
alreadi
posit
still
posit
parvoviru
month
one
patient
viral
load
copyml
month
anoth
patient
viral
load
copyml
symptom
anemia
durat
cytopenia
first
day
differ
without
parvoviru
viremia
parvoviru
infect
found
statist
differ
mrd
patient
vs
p
parvoviru
infect
differ
patient
haplo
hsct
respiratori
virus
manifest
upper
respiratori
tract
infect
four
patient
rsv
two
patient
parainfluenza
two
patient
coronaviru
one
patient
none
pneumonia
among
patient
patient
develop
adv
infect
adv
infect
seen
nine
patient
day
tabl
ten
patient
local
adv
diseas
gastrointestin
tract
without
viremia
four
patient
adv
diseas
viremia
patient
adv
viremia
treat
cidofovir
success
adv
infect
seem
significantli
higher
incid
patient
p
p
incid
adv
infect
statist
differ
fourteen
recipi
allogen
graft
pass
away
first
day
cumul
incid
trm
day
patient
eleven
patient
meanwhil
viral
infect
seven
multipl
viral
infect
patient
patient
pass
away
end
nineteen
multipl
viral
infect
four
patient
one
associ
cmv
hepat
develop
cmv
pneumonia
fatal
outcom
cumul
incid
trm
end
patient
patient
meanwhil
viral
infect
viral
infect
estim
overal
surviv
patient
day
end
overal
surviv
cumul
incid
trm
summar
tabl
overal
surviv
influenc
one
multipl
viral
infect
p
p
trm
day
statist
signific
four
group
trm
end
found
statist
signific
p
signific
especi
promin
mrd
p
p
p
comparison
overal
surviv
end
four
group
associ
significantli
better
surviv
mrd
group
log
rank
test
p
viral
infect
due
impair
immun
reconstitut
remain
caus
morbid
mortal
hsct
patient
incid
viral
infect
best
indic
immun
recoveri
studi
pediatr
patient
second
largest
studi
report
incid
viru
infect
children
follow
allogen
hsct
found
viral
infect
especi
common
first
day
suggest
immun
reconstitut
allogen
hsct
children
sever
acut
gvhd
like
develop
multipl
viral
infect
probabl
due
prolong
intens
immunosuppress
treatment
especi
use
corticosteroid
largest
studi
hiwarkar
et
consist
pediatr
patient
mrd
mud
ag
donor
report
cmv
adv
ebv
frequent
period
lymphopenia
found
adv
ebv
reactiv
addit
associ
use
graft
rustia
et
studi
third
largest
studi
pediatr
patient
mrd
mud
found
similar
incid
result
cmv
adv
ebv
like
hiwarkar
et
al
studi
found
bk
viru
cmv
reactiv
significantli
low
mrd
transplant
patient
compar
best
knowledg
studi
studi
compar
viral
incid
mrdmud
hsct
detect
incid
cmv
reactiv
ofmrd
patient
hsct
recipi
posit
cmv
reactiv
differ
explain
ethnic
geograph
differ
cmv
seropreval
turkish
countri
seropreval
rate
age
group
year
detect
bk
viru
second
seen
viru
studi
bk
viru
frequent
presenc
mud
cord
blood
transplant
gvhd
advanc
age
persist
also
found
bk
viru
frequent
among
recipi
mrd
graft
adv
increasingli
recogn
import
pathogen
recipi
allogen
report
mortal
patient
sustain
high
adv
dna
level
plasma
remark
high
vari
differ
studi
patient
hsct
patient
hsct
patient
develop
adv
infect
import
clinic
manifest
ebv
infect
ptld
occur
patient
found
nine
patient
show
ebv
reactiv
interestingli
detect
lack
ptld
report
also
kanakri
et
crocchiolo
et
parvoviru
caus
rare
signific
infecti
complic
predomin
clinic
manifest
parvoviru
diseas
anemia
chronic
recurr
anemia
well
pure
red
cell
aplasia
may
seen
organ
invas
manifest
hepat
myocard
pneumon
also
observ
rahiala
et
report
studi
incid
parvoviru
detect
incid
parvoviru
major
patient
transplant
haploident
donor
studi
outcom
patient
viral
infect
yan
et
report
studi
haploident
hsct
correl
higher
incid
overal
mortal
trm
compar
sibl
donor
hsct
found
incid
mortal
higher
sibl
donor
hsct
vs
p
rustia
et
found
studi
similarli
overal
surviv
patient
viremia
viral
diseas
significantli
lower
compar
without
viremia
vs
p
viral
diseas
vs
p
studi
overal
surviv
compar
among
patient
wherea
overal
surviv
superior
patient
p
similar
studi
presenc
one
multipl
viral
infect
overal
surviv
found
significantli
lower
compar
without
viral
infect
p
p
hsct
led
highest
incid
trm
day
compar
mrd
haplo
hsct
vs
signific
statist
borderlin
p
associ
superior
trm
hsct
end
p
base
observ
haploident
donor
option
could
becom
second
choic
suitabl
mrd
term
viral
infect
main
limit
studi
retrospect
design
absenc
routin
surveil
outpati
except
cmv
surveil
virus
perform
clinic
suspicion
frequenc
infect
might
underestim
conclus
cmv
bk
viru
infect
found
significantli
low
studi
mud
compar
set
viral
infect
state
previou
studi
despit
antivir
prophylaxi
treatment
viral
infect
associ
reduc
overal
surviv
increas
hospit
complic
significantli
prevent
good
preemptiv
treatment
without
clinic
diseas
reason
especi
countri
take
long
time
find
suitabl
donor
viral
diseas
interfer
decis
consid
time
spent
patient
larger
studi
group
prospect
studi
need
confirm
observ
patient
viral
diseas
potenti
widespread
applic
lymphocyt
therapi
may
like
reduc
morbid
mortal
da
go
conceptdesign
da
aa
data
analysisinterpret
da
data
collect
draft
manuscript
write
aa
statist
fe
data
review
interpret
go
critic
revis
articl
approv
articl
